Particle.news
Clinical Trials Therapeutics Combination Therapy Natural Compounds FDA Approval Cancer Treatments NSAIDs Repurposing Drugs Drug Repurposing Clinical Research Hormone Regulation Neurological Diseases Peptide Drugs Cancer Therapies Taste Receptors ABHD6 Inhibitors Cellular Mechanisms Treatment Strategies Steroids Antiviral Agents Targeted Therapies Enzyme Inhibitors Dosage Optimization Small-Molecule Drugs Metabolic Health Nucleoside Reverse Transcriptase Inhibitors Anti-inflammatory Agents Therapeutic Approaches Drug Mechanisms PDE3 Inhibitors Anticoagulants G Protein-Coupled Receptors Ambroxol GLP-1 Receptor Agonists Anticancer Agents Kinase Inhibitors Topical Treatments Addiction Treatment Carbohydrate-based Drugs Molecular Targeting Cyclophilin Inhibitors Insecticides Biased Signaling Zileuton Asthma Treatments Antidepressants Targeted Therapy Seizure Medications Central Nervous System Drugs Small Molecules Antibiotics Cholesterol Drugs ALOX15 Expression KDS12025 Anticancer Drugs Antibody-Drug Conjugates Racetam Class Chagas Disease Treatment Anti-inflammatory Drugs Investigational Drugs Appetite Stimulants Naloxone Enhancement Opioid Receptors Opioid Overdose Treatment Opioid Withdrawal Research and Development Compound Screening Cancer Drugs Biological Agents GSM-15606
The Nature study repurposes a racecadotril metabolite by matching a regenerative gene signature to existing drugs.
